Best Spirometry Podcasts (2025)

1
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment

Play Pause

6d ago

—

Race-based spirometry adjustments have long influenced pulmonary risk assessments, often underestimating disease severity in Black patients. Hear from Dr. Ajay Sheshadri as he examines the historical misuse of race in lung function testing, explores race-neutral modeling in surgical risk prediction, and highlights the need for data-driven, continuo…

1
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy

3d ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Michael Wang, MD For patients with mantle cell lymphoma (MCL) who relapse after BTK inhibitor (BTKi) therapy, treatment decisions can be complex and time sensitive. That’s why understanding how tumor biology and risk features can guide selection between immunomodulatory regimens and CAR T-cell therapy…

1
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice

6d ago

—

As medicine shifts toward race-neutral lung function interpretation, new challenges emerge in ensuring equitable access to care. Dr. Ajay Sheshadri explores how race-neutral spirometry may impact patient selection for lung resection surgery and hematopoietic cell transplantation. Dr. Sheshadri is an Associate Professor in the Department of Pulmonar…

1
Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative

19d ago

—

A 2025 study in Chest evaluated PREDICT, a precision medicine program at a large academic-community practice, designed to streamline testing and expand access to personalized treatment for non-small cell lung cancer (NSCLC). Hear from ReachMD's Ryan Quigley as he shares the key impacts of this approach and implications for care delivery.…

1
Evaluating Gene Therapy for Sickle Cell Disease: Advantages and Barriers

27d ago

—

Guest: David Jacobsohn Gene therapy is redefining the treatment landscape for sickle cell disease, with approaches like gene addition, gene editing, and fetal hemoglobin induction showing promise in reducing or even eliminating symptoms. However, while these therapies offer some advantages over allogeneic stem cell transplant, they also come with s…

1
Advances in Disease-Modifying and Curative Therapies for Sickle Cell Disease

27d ago

—

Guest: Alexis Leonard Sickle cell disease management traditionally involves two primary treatment approaches: disease-modifying therapies and curative strategies. While disease-modifying therapies can help reduce complications associated with the disease, they do not correct or fix them, which is why curative strategies are appealing to some patien…

1
CRISPR in Sickle Cell: Transforming Care Through Gene Editing

27d ago

—

Guest: Alexis Leonard CRISPR technology, while relatively new, has shown potential in treating patients with sickle cell disease by increasing fetal hemoglobin. Though this gene therapy comes with safety considerations, refinements and advancements in CRISPR technology can offer new management options for sickle cell disease patients. Learn about t…

1
Curative Strategies for Sickle Cell Disease: The Future of Gene Editing

26d ago

—

Guest: Alexis Leonard With two FDA-approved gene therapies, including the first CRISPR-based treatment, curative strategies for sickle cell disease are continuing to expand the treatment landscape. However, challenges remain in optimizing safety and accessibility, particularly for patients unable to tolerate current myeloablative conditioning. Lear…

1
Advances in Follicular Lymphoma Treatment: CAR T-Cell Therapy’s Evolving Role

1M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jonathon B. Cohen, MD, MS As the therapeutic landscape for follicular lymphoma continues to evolve, CAR T-cell therapy is emerging as a transformative option for select patients with relapsed or high-risk disease. But it also comes with a lot of important considerations, like knowing when to refer and…

1
Examining Barriers and Facilitators in Pediatric Sickle Cell Disease Care

1M ago

—

Host: Ashley Baker, MSN, PMHNP Guest: Alyssa Schlenz Guest: Shannon Phillps Families of children with sickle cell disease have noted both an abundance of support and significant obstacles when accessing care, ranging from knowledgeable providers and flexible scheduling to transportation concerns and insurance holdups. Joining Ashley Baker to discus…

1
Predicting Hydroxyurea Resistance in Polycythemia Vera with Machine Learning

1M ago

—

Host: Hallie Blevins, PhD. Early resistance to hydroxyurea in patients with polycythemia vera (PV) is associated with higher risks of thromboembolic complications, disease progression, and mortality. The PV-AIM study applied machine learning to real-world data and identified simple lab-based predictors that stratify patients by risk, and these find…

1
Beyond Disease Control: PROs With Odronextamab in R/R Follicular Lymphoma

1M ago

—

Host: Ryan Quigley In relapsed or refractory follicular lymphoma, disease control is only part of the equation. In this AudioAbstract, ReachMD's Ryan Quigley explores patient-reported outcomes from the ELM-2 trial, revealing that odronextamab not only delivers high response rates but also helps preserve—and in some cases, improve—quality of life.…

1
Examining Real-World Ibrutinib Outcomes in R/R MCL: Findings from a Danish Study

1M ago

—

Host: Marlene Mimi Maeusli, PhD. A recent Danish population-based study evaluating real-world outcomes of ibrutinib in relapsed or refractory mantle cell lymphoma (MCL) found lower efficacy and tolerability compared to clinical trials, particularly among older patients and those with high-risk disease features. In this AudioAbstract, ReachMD's Dr. …

1
Expanding the Risk Profile: Genetic Insights Into Lung Cancer in Non-Smokers

2M ago

—

Guest: Paola Marignani, PhD, EMBA While smoking remains a key risk factor for lung cancer, up to 25 percent of cases occur in people who have never smoked, leaving significant gaps in our understanding of causation and diagnostics. Dr. Paola Marignani explores emerging discoveries in gene variants unique to never-smokers, uncovered through single-c…

1
CAR T in Marginal Zone Lymphoma: Insights from the TRANSCEND FL Study

2M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD CAR T-cell therapies have helped transform the treatment of aggressive lymphomas, but could they also change the game for slower-growing, harder-to-treat diseases like marginal zone lymphoma? Based on new data from the TRANSCEND FL study, liso-cel achieved a 95 percent overall respons…

1
Unlocking Tumor Complexity: Single-Cell RNA Sequencing in Lung Cancer

2M ago

—

Guest: Paola Marignani, PhD, EMBA Single-cell RNA sequencing is transforming our understanding of tumor heterogeneity in primary lung cancers by offering insights far beyond traditional bulk sequencing. In this program, Dr. Paola Marignani explores how advanced machine learning enables faster, more precise profiling of genetic diversity, predictive…

1
CAR T and Bispecifics in LBCL: Redefining Second-Line Therapy Choices

2M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Samuel Yamshon, MD The treatment landscape for large B-cell lymphoma (LBCL) is rapidly evolving due to the growing integration of bispecific antibodies into second-line care. While these agents offer promising, targeted options—not only for patients ineligible for CAR T-cell therapy, but also as compl…

1
Refining Multimodal Therapy for Mesothelioma: Clinical Impact of SMART Sequencing

2M ago

—

Guest: John Cho, MD, PhD, FRCPC Surgery for mesothelioma after radiation therapy (SMART) offers new hope for patients with resectable epithelioid mesothelioma by reversing the traditional treatment sequence. Hear from Dr. John Cho as he discusses the rationale behind this decade-long clinical advancement, which he spoke about at the 2025 World Conf…

1
From Policy to Practice: What the WHO Lung Health Resolution Means for Lung Cancer Care

2M ago

—

Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.…

1
The SMART Protocol in Mesothelioma: Challenges and Opportunities for Global Adoption

2M ago

—

Guest: John Cho, MD, PhD, FRCPC While early findings using the SMART protocol for mesothelioma have been encouraging, replication has proven challenging due to steep surgical learning curves, complexities in planning, and skepticism. Dr. John Cho explores why adoption has been limited and what's next for this approach, which he discussed at the 202…

1
Expanding Cancer Detection: How MCED Testing Complements Standard Screening

2M ago

—

Guest: Jennifer Caudle, DO Host: Patrick McGill, MD Current cancer screening guidelines cover just five cancers—breast, lung, colon, prostate, and cervical—leaving many aggressive cancers undetected until later stages. But multi-cancer early detection (MCED) testing is reshaping the landscape with blood-based analyses of cell-free DNA and methylati…

1
Rethinking Cancer Screening: The Rationale for Multi-Biomarker MCED Testing

2M ago

—

Host: Brian P. McDonough, MD, FAAFP Guest: Marie Wood, MD Traditional cancer screening has always focused on individual organs, but now, multi-cancer early detection (MCED) tests are changing that paradigm. By analyzing multiple biomarkers through a single blood draw, MCED testing can detect signals from a variety of cancers—many of which currently…

1
Integrating MCED Testing in Practice: Best Practices for Enhancing Cancer Screening

2M ago

—

Host: Brian P. McDonough, MD, FAAFP Guest: Mylynda Massart, MD, PhD Given its ability to identify universal cancer signals across multiple tumor types, multi-cancer early detection (MCED) testing is emerging as a promising tool to complement traditional, single-cancer screening methods. Joining Dr. Brian McDonough to share practical strategies for …

1
Advancing Noninvasive CRC Screening: Exploring an Aptamer-Based Assay

2M ago

—

Host: Ryan Quigley Guest: Hallie Blevins, PhD. Guest: Marlene Mimi Maeusli, PhD. With one in three eligible Americans still unscreened for colorectal cancer (CRC), there’s an urgent need for noninvasive and affordable alternatives to colonoscopy. A 2025 study published in ACS Sensors introduces a novel aptamer-based colorimetric assay that targets …

1
Redefining Cancer Care with Functional Precision Medicine

2M ago

—

Host: Matt Birnholz, MD Guest: Jim Foote, MBA Functional precision medicine is reshaping oncology by integrating real-time drug testing, genomic data, and artificial intelligence to guide individualized treatment. Dr. Matt Birnholz sits down with Jim Foote, CEO of First Ascent Biomedical, to explore how this approach delivers clinically actionable …

1
Optimizing Second-Line CAR T Decisions in R/R Large B-Cell Lymphoma

3M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD The treatment landscape for relapsed/refractory (R/R) large B-cell lymphoma has significantly shifted, with CAR T-cell therapies now offering curative potential in the second-line setting. But these advances also raise important questions, like how to identify the right candidates and…

1
Enhancing Efficacy and Safety in HR+/HER2- Breast Cancer with Novel PI3Kα Inhibitors

3M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Due to their wild-type inhibition, first-generation PIK3CA inhibitors for HR+/HER2- advanced breast cancer were limited by significant toxicities, including hyperglycemia, rash, and diarrhea. But now, mutation-specific PIK3CA inhibitors could help improve tolerability and adherence…

1
Targeting PI3Kα-Mutated HR+/HER2- Breast Cancer in the Second-Line Setting

3M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Neil M. Iyengar, MD Guest: Komal Jhaveri, MD, FACP The second-line treatment of HR+/HER2-advanced breast cancer has evolved in recent years, particularly with the rise of biomarker-driven strategies targeting PI3Kα and other mutations. But given these advances, there’s a lot we need to think about whe…

1
Advancing Endometrial Cancer Care: ADCs and Biomarker-Based Therapies

3M ago

—

Guest: Brian Slomovitz, MD Our treatment approach for patients with endometrial cancer is evolving, with antibody-drug conjugates (ADCs) and biomarker-driven therapies showing promise. Dr. Brian Slomovitz highlights future directions that could redefine treatment pathways for patients with advanced or recurrent disease. Dr. Slomovitz is the Directo…

1
Optimizing PI3Kα Testing and Therapy in HR+/HER2- Advanced Breast Cancer Care

3M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO Not only is PI3Kα the most common mutation seen in patients with HR+/HER2- advanced breast cancer, but it’s also associated with endocrine therapy resistance and more aggressive cancer growth. Given its prevalence and impact on outcomes, it’s important to know how and when to t…

1
Pediatric Sickle Cell Disease: Analyzing Trends in Medication Utilization

3M ago

—

Guest: Abiodun Ologunowa Pediatric sickle cell disease treatment, particularly the use of hydroxyurea, NSAIDs, and opioids, has evolved in response to clinical guidelines and regulatory shifts, but gaps still remain in how children receive essential medications. Joining Dr. Charles Turck to discuss these national prescribing trends, disparities in …

1
Trailer 2.0 1:39

3M ago1:39

1:39

By Guy Deutschman

1
Analyzing Toxicity Trends Post-CAR T-Cell Therapy: Implications for Patient Monitoring

3M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Manali Kamdar, MD Although CAR T-cell therapies have transformed the treatment of B-cell malignancies, a major logistical and socioeconomic barrier remains: patients are typically required to stay near a certified treatment center for at least 4 weeks after infusion to manage potential adverse events.…

1
Sickle Cell Disease Care: Balancing Disease-Modifying and Curative Therapies

3M ago

—

Guest: Yogindra Persuad Despite the promise of curative therapies for sickle cell disease, access and cost barriers highlight the ongoing need for disease-modifying treatments like hydroxyurea. Tune in to hear Dr. Yogindra Persuad, a physician in the Department of Hematology at St. Jude Children’s Research Hospital in Memphis, Tennessee, discuss a …

1
Balancing Benefits and Risks in Emerging Sickle Cell Therapies

3M ago

—

Guest: Yogindra Persuad For decades, hydroxyurea has been the cornerstone therapy for sickle cell disease, but new disease-modifying therapies, curative strategies, and gene therapies are expanding options for patients. While these advancing approaches come with some risks, they can help offer symptom relief, reduce complications, and give patients…

1
Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks

3M ago

—

Guest: Parul Rai Cardiopulmonary complications are a leading cause of early mortality in adults with sickle cell disease, with evidence showing that cardiac injury may begin as early as childhood. However, despite the severity of these issues, there are currently no uniform guidelines for asymptomatic cardiac screening in this population. Join Dr. …

1
The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease

3M ago

—

Guest: Nidhi Bhatt Effective transition from pediatric to adult care should begin as early as age twelve for patients with sickle cell disease, incorporating factors like education, self-advocacy skills, and support from transition care coordinators. Tune in to hear Dr. Nidhi Bhatt, who works in the Department of Hematology at St. Jude Children’s H…

1
Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions

3M ago

—

Guest: Parul Rai Hydroxyurea and chronic transfusions remain cornerstone therapies in managing sickle cell disease, with proven benefits in reducing stroke risk and improving anemia. However, considerations remain, including their impact on cardiac health. Learn about these long-standing therapies and best practices for using them to manage sickle …

1
The Blown Values Podcast Trailer 1:36

3M ago1:36

1:36

By Guy Deutschman

1
Debunking CAR T-Cell Myths: The Realities of Patient Selection, Safety, and Access

4M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Lunning, DO, FACP Despite FDA approvals and growing clinical integration, CAR T-cell therapies remain clouded by misconceptions, some of which could impact clinical decision-making and delay appropriate referrals. To help set the record straight on CAR T-cell therapy, Dr. Charles Turck speaks …

1
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care

5M ago

—

Guest: Jorge Nieva, MD As cancer treatment continues to evolve, at-home subcutaneous immunotherapy is at the forefront of decentralized care and research. Here to share his insights on how this delivery model could impact clinical trials and cancer care is Dr. Jorge Nieva, Associate Professor of Clinical Medicine at the University of Southern Calif…

1
Bringing Cancer Care Home: How Subcutaneous Immunotherapy Can Help Ease the Burden

5M ago

—

Guest: Jorge Nieva, MD As immunotherapy becomes a cornerstone for treating a growing number of solid tumors, reducing the logistical burden of in-office care is essential. Fortunately, the at-home administration of subcutaneous formulations of immunotherapy agents like atezolizumab could help transform the way we care for patients with cancer. Lear…

1
Unpacking the Logistics of At-Home Subcutaneous Cancer Immunotherapy Delivery

5M ago

—

Guest: Jorge Nieva, MD Despite the promising benefits for cancer patients, the at-home administration of subcutaneous immunotherapy poses complex operational and logistical challenges, like cost, payer preferences, and patient safety. Tune in to hear Dr. Jorge Nieva discuss these key factors and considerations impacting the implementation of at-hom…

1
Investigating At-Home Subcutaneous Atezolizumab for NSCLC: An Ongoing Study

5M ago

—

Guest: Jorge Nieva, MD Can the immune checkpoint inhibitor atezolizumab be safely administered subcutaneously at home for patients with non-small cell lung cancer (NSCLC)? That’s the exact question an ongoing study is seeking to answer, and here to discuss the study’s objective, design, and potential implications for home-based subcutaneous cancer …

1
First Results From Cohort 4 of the SunRISe-1 Trial

6M ago

—

This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder cancer (NMIBC). Dr. Shore presents key findings from the SunRISe-1 trial, highlighting 1-year durability and patient-reported outcomes data in BCG-unres…

1
Trial in Progress: Phase 3 MoonRISe-3 Study

6M ago

—

This series of video briefs features Dr. Neal Shore reporting from AUA 2025 in Las Vegas. Tune in for timely updates on innovatively delivered intravesical therapies for non–muscle invasive bladder cancer (NMIBC). Dr. Shore presents key findings from the SunRISe-1 trial, highlighting 1-year durability and patient-reported outcomes data in BCG-unres…

1
HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

7M ago

—

Guest: Fernando López-Ríos, MD, PhD Guest: Christian Rolfo, MD, PhD Guest: Charlie Gourley, MD, PhD In this on-demand replay of a recent interactive webinar, renowned experts Prof. Fernando López-Ríos, Prof. Christian Rolfo, and Prof. Charlie Gourley review the latest data, guidelines, and patient cases as they explore best practices for HER2 testi…

1
Advancing Cancer Care: Key Considerations for Subcutaneous Immunotherapies

7M ago

—

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Hadfield, MD Subcutaneous cancer immunotherapies may offer a faster, more resource-efficient alternative to intravenous administration, improving patient convenience and accessibility while maintaining efficacy. However, careful monitoring for immunotherapy-related toxicities remains essential…

1
Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

7M ago

—

Host: Elizabeth R. Plimack, MD, MS, FASCO Guest: Shilpa Gupta, MD New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and a…